Piramal Pharma
Piramal Pharma Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Piramal Pharma
Start SIPPiramal Pharma Investment Rating
-
Master Rating:
-
Piramal Pharma has an operating revenue of Rs. 8,012.92 Cr. on a trailing 12-month basis. An annual revenue growth of 6% is not great, Pre-tax margin of 14% is healthy, ROE of 6% is fair but needs improvement. The company has a reasonable debt to equity of 9%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 4 which is a POOR score indicating inconsistency in earnings, a RS Rating of 1 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D- which indicates heavy supply, Group Rank of 93 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of E is the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Dec 2022 | Sep 2022 | Jun 2022 |
|---|---|---|---|
| Oper Rev Qtr Cr | 813 | 829 | 746 |
| Operating Expenses Qtr Cr | 786 | 782 | 813 |
| Operating Profit Qtr Cr | 27 | 47 | -66 |
| Depreciation Qtr Cr | 47 | 47 | 45 |
| Interest Qtr Cr | 33 | 29 | 20 |
| Tax Qtr Cr | 3 | 35 | -7 |
| Net Profit Qtr Cr | -2 | 47 | -17 |
Piramal Pharma Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 3
- Bearish Moving Average
- ___
- 10
- 20 Day
- 74.58
- 50 Day
- 89.1
- 100 Day
- 112.29
- 200 Day
- 20 Day
- 74.02
- 50 Day
- 90.4
- 100 Day
- 111.71
- 200 Day
Piramal Pharma Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 69.87 |
| Second Resistance | 71.29 |
| Third Resistance | 72.12 |
| RSI | 27.6 |
| MFI | 30.46 |
| MACD Single Line | -7.12 |
| MACD | -6.49 |
| Support | |
|---|---|
| First Resistance | 67.62 |
| Second Resistance | 66.79 |
| Third Resistance | 65.37 |
Piramal Pharma Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 5,084,542 | 265,667,320 | 52.25 |
| Week | 4,761,370 | 246,734,214 | 51.82 |
| 1 Month | 3,825,278 | 217,122,758 | 56.76 |
| 6 Month | 4,109,055 | 265,157,308 | 64.53 |
Piramal Pharma Result Highlights
Piramal Pharma Synopsis
NSE-Medical-Diversified
Piramal Pharma belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 3094.95 Cr. and Equity Capital is Rs. 1185.91 Cr. for the Year ended 31/03/2022. Piramal Pharma Ltd. is a Public Limited Listed company incorporated on 04/03/2020 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is U24297MH2020PLC338592 and registration number is 338592.| Market Cap | 8,335 |
| Sales | 5,484 |
| Shares in Float | 77.57 |
| No of funds | 242 |
| Yield |
| Book Value | 1.63 |
| U/D Vol ratio | 0.3 |
| LTDebt / Equity | 9 |
| Alpha | -0.73 |
| Beta | 1.25 |
Piramal Pharma
| Owner Name | Dec-22 | Oct-22 |
|---|---|---|
| Promoters | 34.79% | 34.79% |
| Mutual Funds | 0.51% | 0.54% |
| Insurance Companies | 4.17% | 4.22% |
| Foreign Portfolio Investors | 21.29% | 27.36% |
| Financial Institutions/ Banks | ||
| Individual Investors | 11.8% | 7.42% |
| Others | 27.44% | 25.67% |
Piramal Pharma Management
| Name | Designation |
|---|---|
| Mrs. Nandini Piramal | Chairperson |
| Mr. Peter DeYoung | Executive Director |
| Mr. Vivek Valsaraj | Executive Director & CFO |
| Mr. Neeraj Bharadwaj | Non Executive Director |
| Mr. S Ramadorai | Independent Director |
| Mr. Jairaj Purandare | Independent Director |
| Mr. Peter Stevenson | Independent Director |
| Mr. Sridhar Gorthi | Independent Director |
| Mr. Nathalie Leitch | Non Executive Director |
| Ms. Vibha Paul Rishi | Independent Director |
Piramal Pharma Forecast
Price Estimates
Piramal Pharma FAQs
What is Share Price of Piramal Pharma ?
Piramal Pharma share price is ₹69 As on 24 March, 2023 | 01:39
What is the Market Cap of Piramal Pharma ?
The Market Cap of Piramal Pharma is ₹8335.3 Cr As on 24 March, 2023 | 01:39
What is the P/E ratio of Piramal Pharma ?
The P/E ratio of Piramal Pharma is As on 24 March, 2023 | 01:39
What is the PB ratio of Piramal Pharma ?
The PB ratio of Piramal Pharma is As on 24 March, 2023 | 01:39